Trevi Therapeutics, Inc. $TRVI Holdings Lessened by Fifth Third Bancorp

Fifth Third Bancorp lessened its holdings in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) by 19.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 209,640 shares of the company’s stock after selling 51,004 shares during the period. Fifth Third Bancorp’s holdings in Trevi Therapeutics were worth $3,002,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. KBC Group NV purchased a new stake in shares of Trevi Therapeutics in the 1st quarter valued at $29,000. Sterling Capital Management LLC increased its position in Trevi Therapeutics by 848.7% during the third quarter. Sterling Capital Management LLC now owns 3,567 shares of the company’s stock worth $51,000 after purchasing an additional 3,191 shares during the last quarter. Avidity Partners Management LP purchased a new stake in Trevi Therapeutics in the 1st quarter valued at about $79,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Trevi Therapeutics in the third quarter valued at $104,000. Finally, Amundi acquired a new stake in Trevi Therapeutics during the 2nd quarter worth approximately $192,000. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Trevi Therapeutics

In other Trevi Therapeutics news, Director Michael Heffernan sold 39,473 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $15.09, for a total transaction of $595,647.57. Following the completion of the transaction, the director owned 6,351 shares in the company, valued at $95,836.59. This trade represents a 86.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 15.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on TRVI shares. Oppenheimer reaffirmed an “outperform” rating on shares of Trevi Therapeutics in a report on Friday, September 25th. Wall Street Zen downgraded Trevi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. BMO Capital Markets restated an “outperform” rating on shares of Trevi Therapeutics in a research report on Wednesday, October 7th. JonesTrading boosted their price target on Trevi Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. Finally, Cantor Fitzgerald boosted their target price on Trevi Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.09.

Get Our Latest Research Report on Trevi Therapeutics

Trevi Therapeutics Stock Up 1.6%

TRVI opened at $13.72 on Friday. The business has a 50 day simple moving average of $13.78 and a two-hundred day simple moving average of $14.54. Trevi Therapeutics, Inc. has a one year low of $9.82 and a one year high of $20.22.

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). Research analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

About Trevi Therapeutics

(Free Report)

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for chronic cough and chronic itch. Its lead candidate, Haduvio (oral extended-release nalbuphine), is being studied for conditions including idiopathic pulmonary fibrosis, other interstitial lung diseases and chronic pruritus associated with prurigo nodularis. Nalbuphine acts on opioid receptors, and Trevi is evaluating its potential to reduce these symptoms. The company’s development programs are focused on clinical research; Haduvio is not an approved treatment.

Recommended Stories

Want to see what other hedge funds are holding TRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report).

Institutional Ownership by Quarter for Trevi Therapeutics (NASDAQ:TRVI)

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.